These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target. Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519 [TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439 [TBL] [Abstract][Full Text] [Related]
5. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014 [TBL] [Abstract][Full Text] [Related]
6. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies. Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109 [TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Jothi M; Mal M; Keller C; Mal AK Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448 [TBL] [Abstract][Full Text] [Related]
9. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785 [TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
11. Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of "Fusion-Positive" Cases. Dermawan JK; Malik F; Gross JM; Baraban E; Pratilas C; Mneimneh W; Trucco M; Sun W; Barr FG; D'Almeida Costa F; Fritchie KJ Mod Pathol; 2024 Nov; 37(11):100594. PubMed ID: 39147032 [TBL] [Abstract][Full Text] [Related]
12. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features. Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003 [TBL] [Abstract][Full Text] [Related]
13. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
14. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
15. Evidence of pioneer factor activity of an oncogenic fusion transcription factor. Sunkel BD; Wang M; LaHaye S; Kelly BJ; Fitch JR; Barr FG; White P; Stanton BZ iScience; 2021 Aug; 24(8):102867. PubMed ID: 34386729 [TBL] [Abstract][Full Text] [Related]
16. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413 [TBL] [Abstract][Full Text] [Related]
18. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
19. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]
20. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]